Monte Rosa Therapeutics (GLUE) Net Cash Flow Growth (3y) (2023 - 2026)
Monte Rosa Therapeutics (GLUE) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 32.17% |
| 10 | Monte Rosa Therapeutics | 2.27 Bn | 1.59 Bn | - | 127.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127.58% |
| Dec 31, 2025 | -10.94% |
| Sep 30, 2025 | 152.08% |
| Jun 30, 2025 | 36.13% |
| Mar 31, 2025 | 11.16% |
| Dec 31, 2024 | 97.33% |
| Sep 30, 2024 | 18.91% |
| Jun 30, 2024 | -63.64% |
| Mar 31, 2024 | -30.48% |
| Dec 31, 2023 | 108.57% |
| Sep 30, 2023 | -32.97% |